Vasculitis nursing: assessment, classification, and care

Vasculitis is a heterogeneous group of conditions defined by inflammatory destruction of blood vessel walls. The inflammation may involve vessels of any size — large, medium, or small — and in any organ system, producing an exceptionally wide range of clinical presentations: from a child with purpura and joint pain following a respiratory illness, to an older adult with sudden jaw pain and vision loss, to a middle-aged patient with simultaneous sinus destruction, hemoptysis, and rapidly progressive glomerulonephritis. Because the presentations cross specialties and mimic many other serious diseases, recognition, timely escalation, and targeted nursing assessment are high-stakes skills.

This reference covers the primary systemic vasculitides organized by vessel size — the framework used in ACR/EULAR classification — with focused sections on ANCA-associated vasculitis (the highest-stakes category for nurses to recognize), nursing assessment priorities, pharmacology, and NCLEX differentiation.

For autoimmune overlap context, see lupus nursing, rheumatoid arthritis nursing, and scleroderma nursing.

Vasculitis classification by vessel size

Large-vessel vasculitis

Giant cell arteritis (GCA)

Giant cell arteritis, also called temporal arteritis, is the most common primary vasculitis in adults in the United States, predominantly affecting individuals over age 50 — the ACR classification criteria require this age threshold. It is approximately three times more common in women than men and has the highest incidence in populations of northern European ancestry.

Pathophysiology and vessels affected. GCA is a granulomatous inflammation of large and medium arteries, with a predilection for branches of the aorta and the external carotid artery — particularly the superficial temporal, ophthalmic, posterior ciliary, and occipital arteries. Less commonly, it involves the aorta itself or its primary branches, occasionally causing aortic aneurysm years after the acute presentation.

Clinical presentation. The classic triad is new-onset headache (typically temporal), scalp tenderness, and jaw claudication. Jaw claudication — jaw pain or fatigue with chewing, caused by ischemia to the masseter muscle — is the single most specific symptom for GCA. Additional features include temporal artery tenderness or nodularity on palpation, fever, malaise, and unintentional weight loss. Polymyalgia rheumatica (PMR) — aching and stiffness of the shoulder and hip girdle — co-occurs in 40–50% of GCA patients and is an important clinical association to recognize.

Vision loss: the critical complication. The most feared complication of GCA is anterior ischemic optic neuropathy (AION), caused by inflammation of the posterior ciliary arteries that supply the optic nerve. AION produces sudden, painless, monocular vision loss — often described by patients as a curtain descending over the visual field. Without immediate treatment, the vision loss is typically permanent. Any patient with suspected GCA who develops visual symptoms must be treated with high-dose corticosteroids the same day — this is an ophthalmologic emergency. Delay to treatment is a primary cause of bilateral blindness in GCA.

Diagnostics. ESR is elevated in more than 95% of active GCA cases, typically above 50 mm/hr and often above 100 mm/hr. CRP is also elevated and may be a more sensitive marker of active disease. Temporal artery biopsy is the gold standard — a segment of at least 2 cm is required due to skip lesions (areas of normal-appearing artery between inflamed segments). A negative biopsy does not exclude GCA if clinical suspicion is high. Vascular ultrasound of the temporal arteries showing a hypoechoic halo sign (“halo sign”) is increasingly used as a non-invasive diagnostic tool.

Treatment. High-dose prednisone — typically 40–60 mg/day orally for uncomplicated GCA, or IV methylprednisolone 1 g/day for 3 days when vision is threatened — is started immediately upon clinical diagnosis, before biopsy if necessary. Prednisone is then tapered slowly over 12–18 months. Tocilizumab (IL-6 receptor inhibitor) is FDA-approved as a steroid-sparing agent for GCA, significantly reducing relapse rates and cumulative corticosteroid exposure.

Nursing priorities for GCA:

• Ask about jaw claudication and scalp tenderness at every assessment — these are specific for GCA and often missed on initial encounter.
• Any patient with GCA reporting new visual symptoms (blurring, diplopia, vision loss) is experiencing an emergency. Escalate immediately.
• Educate patients on long-term corticosteroid effects: weight gain, hyperglycemia, hypertension, osteoporosis, adrenal suppression. Calcium, vitamin D, and bisphosphonate co-prescription is standard.
• Monitor ESR and CRP as disease activity markers during steroid taper.

Takayasu arteritis

Takayasu arteritis is a large-vessel granulomatous vasculitis involving the aorta and its primary branches, with particular predilection for the branches of the aortic arch — the subclavian, carotid, vertebral, and renal arteries. Unlike GCA, Takayasu predominantly affects young women, with onset typically before age 40 and peak incidence in the second and third decades. It is more common in Asian populations.

Clinical presentation. Early disease is characterized by systemic features — fever, fatigue, weight loss, arthralgia, and elevated inflammatory markers — before vessel stenosis or occlusion becomes apparent. Late disease is dominated by the consequences of progressive arterial narrowing: absent or diminished pulses (the condition is sometimes called “pulseless disease”), blood pressure differentials between arms greater than 10 mmHg, bruits over the carotid or subclavian arteries, claudication of the arms or jaw, and hypertension from renal artery stenosis. Stroke and aortic regurgitation are serious complications of advanced disease.

Diagnostics. Elevated ESR and CRP during active disease. CT angiography, MR angiography, or conventional angiography demonstrates vessel wall thickening, stenosis, occlusions, and aneurysms. PET scan may identify active inflammation before structural changes appear.

Treatment. High-dose corticosteroids are the cornerstone of induction. Methotrexate, azathioprine, mycophenolate, and tocilizumab are used for refractory or relapsing disease. Surgical bypass or endovascular intervention may be needed for critical vessel stenosis — ideally deferred until disease activity is controlled.

Nursing priorities for Takayasu:

• Measure blood pressure in both arms at every encounter — a differential greater than 10 mmHg is a clinical finding, not a measurement artifact.
• Assess bilateral radial, brachial, and femoral pulses with each assessment. Document the presence or absence of each.
• Hypertension from renal artery stenosis may be difficult to control and predisposes to stroke — blood pressure management is a critical nursing intervention.

ANCA-associated vasculitis (AAV)

ANCA-associated vasculitides are the most clinically urgent group for nurses to recognize. They can progress from constitutional symptoms to respiratory failure or dialysis-dependent renal failure within weeks. All three share small-vessel involvement, pauci-immune inflammation (few immune deposits on biopsy, unlike immune-complex vasculitis), and the ability to cause pulmonary-renal syndrome — simultaneous alveolar hemorrhage and glomerulonephritis.

GPA (granulomatosis with polyangiitis)

Formerly called Wegener’s granulomatosis, GPA is the most common ANCA-associated vasculitis in adults and the one most heavily tested in nursing education.

The ENT–lung–kidney triad. GPA characteristically involves three organ systems simultaneously:

1. Upper respiratory tract (ENT): Chronic sinusitis that does not respond to antibiotics, recurrent epistaxis, oral ulcers, subglottic stenosis. As granulomatous inflammation destroys the nasal cartilage and septum, patients develop the saddle-nose deformity — a collapse of the nasal bridge that is essentially pathognomonic for GPA when combined with other features. Otitis media, hearing loss, and orbital involvement (proptosis) may also occur.

2. Lower respiratory tract: Hemoptysis, dyspnea, pulmonary infiltrates, and pulmonary nodules — some of which may cavitate. Diffuse alveolar hemorrhage (DAH), the most life-threatening pulmonary manifestation, presents as progressive respiratory failure with hemoptysis and diffuse bilateral infiltrates. DAH is a medical emergency requiring ICU admission and immediate immunosuppression.

3. Renal: Rapidly progressive glomerulonephritis (RPGN) presenting as hematuria, proteinuria, RBC casts in urinary sediment, and rising creatinine. Renal involvement can progress to dialysis-dependent failure within days to weeks without treatment. See CKD and ESRD nursing for renal monitoring framework.

ANCA serology. GPA is associated with c-ANCA (cytoplasmic pattern on immunofluorescence), which corresponds to antibodies against PR3 (proteinase-3). c-ANCA/PR3-ANCA sensitivity for generalized GPA is approximately 75–90%; specificity is high. A positive ANCA should be confirmed with an antigen-specific assay (anti-PR3 or anti-MPO ELISA).

Treatment. Induction of remission uses rituximab (preferred for most patients) or cyclophosphamide combined with high-dose corticosteroids. Rituximab is increasingly preferred over cyclophosphamide due to similar efficacy with a better long-term safety profile (fewer malignancies, less gonadotoxicity). Maintenance therapy uses rituximab, azathioprine, or methotrexate to prevent relapse, which occurs in up to 50% of patients within 5 years. Trimethoprim-sulfamethoxazole is used as prophylaxis against Pneumocystis pneumonia (PJP) given the degree of immunosuppression, and also has some disease-modifying effect in limited upper-airway disease.

EGPA (eosinophilic granulomatosis with polyangiitis)

Formerly called Churg-Strauss syndrome, EGPA is distinguished by the presence of asthma — typically adult-onset, severe, and often refractory — combined with peripheral eosinophilia above 1,500 cells/µL (or greater than 10% on differential) and necrotizing granulomatous inflammation of small vessels.

Clinical phases. EGPA classically progresses through three phases, though they overlap considerably in practice:

1. Prodromal phase: Adult-onset asthma and allergic rhinitis, often preceding vasculitis by years.
2. Eosinophilic phase: Peripheral eosinophilia and eosinophilic tissue infiltration, including eosinophilic pneumonia and gastroenteritis.
3. Vasculitic phase: Small-vessel granulomatous vasculitis producing neuropathy (mononeuritis multiplex), purpura, glomerulonephritis, and cardiac involvement.

Cardiac disease is the leading cause of death in EGPA, occurring in approximately 15–25% of patients. Eosinophilic myocarditis, cardiomyopathy, pericarditis, and endomyocardial fibrosis can all occur. A baseline and periodic echocardiogram is essential in the management of EGPA.

ANCA serology. Only approximately 40% of EGPA patients are ANCA-positive — lower than in GPA or MPA. When present, the pattern is p-ANCA/MPO-ANCA. ANCA-negative EGPA tends to have more eosinophilic organ damage (cardiac, pulmonary) while ANCA-positive EGPA more commonly manifests vasculitic features (renal, neuropathic, purpura).

Treatment. High-dose corticosteroids remain the backbone of induction. Cyclophosphamide is added for severe organ-threatening disease (renal, cardiac, severe neuropathy). Mepolizumab, an anti-IL-5 monoclonal antibody, is FDA-approved for relapsing-remitting EGPA — it reduces eosinophilia and vasculitis relapse rates while allowing steroid tapering.

MPA (microscopic polyangiitis)

MPA is a pauci-immune small-vessel vasculitis that shares features with GPA but has important distinctions:

• No granulomas (granuloma formation is a defining feature of GPA and EGPA, not MPA)
• No upper airway involvement — no sinusitis, no saddle-nose, no subglottic stenosis
• Predominantly renal and pulmonary — pauci-immune glomerulonephritis is almost universal in significant MPA; pulmonary-renal syndrome (alveolar hemorrhage + GN) occurs more commonly in MPA than in GPA

ANCA serology. MPA is associated with p-ANCA/MPO-ANCA in approximately 60–70% of cases. The distinction between MPO-ANCA-positive MPA and MPO-ANCA-positive GPA requires careful clinicopathologic correlation — the granuloma is the key histologic discriminator.

Treatment parallels GPA: rituximab or cyclophosphamide plus corticosteroids for induction; azathioprine or rituximab for maintenance. Patients with pulmonary-renal syndrome require ICU-level care, often including mechanical ventilation and dialysis support. Plasma exchange (PLEX) has historically been considered for severe renal disease, though recent trial evidence (PEXIVAS) showed no mortality benefit — current guidelines do not routinely recommend PLEX for AAV.

Medium-vessel vasculitis

Polyarteritis nodosa (PAN)

PAN is a systemic necrotizing vasculitis of medium-sized arteries, typically involving the renal, mesenteric, and peripheral nerve vessels while conspicuously sparing the pulmonary vasculature and glomerular capillaries (no glomerulonephritis — a critical distinguishing feature from MPA).

HBV association. Approximately 7–10% of PAN cases are associated with hepatitis B virus infection — HBV-related immune complex deposition drives arterial inflammation. The remainder are idiopathic. Hepatitis B vaccination has reduced the incidence of HBV-associated PAN.

Clinical features:

• Mononeuritis multiplex — simultaneous or sequential involvement of multiple individual peripheral nerves in an asymmetric pattern (e.g., foot drop from peroneal nerve involvement plus wrist drop from radial nerve). This is characteristic of medium-vessel vasculitis affecting the vasa nervorum.
• Renal artery aneurysms — detected by angiography; can rupture, causing retroperitoneal hemorrhage
• Renovascular hypertension — from renal artery involvement and ischemia
• Mesenteric ischemia — abdominal pain, GI bleeding
• Skin findings — livedo reticularis, skin ulcers, digital ischemia
• Testicular pain — a classical but under-recognized feature of PAN, resulting from orchitis/epididymitis from vasculitis of testicular arteries

Key differentiating features from AAV:

• ANCA-negative
• No glomerulonephritis
• No pulmonary involvement (no hemoptysis, no alveolar hemorrhage)
• Angiography shows classic microaneurysms and beading of medium arteries

Treatment. Corticosteroids are the primary therapy. Cyclophosphamide is added for severe disease. HBV-associated PAN requires antiviral therapy (tenofovir or entecavir) in addition to short-course corticosteroids.

Kawasaki disease

Kawasaki disease is an acute, self-limited vasculitis of childhood affecting medium-sized vessels, including the coronary arteries. It predominantly affects children under 5 years and is the leading cause of acquired heart disease in children in developed countries.

Diagnostic criteria. Classic Kawasaki requires fever ≥5 days plus at least four of five principal features:

1. Bilateral non-purulent conjunctival injection (redness without discharge)
2. Polymorphous rash (not vesicular or bullous)
3. Changes of the lips and oral cavity (strawberry tongue, lip erythema/cracking, oropharyngeal erythema)
4. Changes of the extremities (edema, erythema of palms/soles in acute phase; periungual desquamation in subacute phase)
5. Cervical lymphadenopathy (≥1 node ≥1.5 cm, typically unilateral)

Coronary artery aneurysms are the feared complication, occurring in approximately 25% of untreated children. IVIG dramatically reduces aneurysm risk to below 5% when given within the first 10 days of fever onset.

Treatment: IVIG + aspirin. This is the one pediatric exception to Reye’s syndrome avoidance. Aspirin is indicated in Kawasaki disease — used at high doses (80–100 mg/kg/day in four divided doses) during the acute febrile phase for its anti-inflammatory effect, then reduced to low-dose antiplatelet therapy (3–5 mg/kg/day) after fever resolves. NCLEX consistently tests that aspirin is appropriate — and indicated — in Kawasaki disease despite Reye’s syndrome precautions in other viral-illness contexts.

IgA vasculitis (Henoch-Schönlein purpura)

IgA vasculitis is the most common systemic vasculitis in children, typically following an upper respiratory tract infection (most commonly streptococcal) by 1–3 weeks. The pathophysiology involves deposition of IgA1-containing immune complexes in small vessel walls — including skin, joints, GI tract, and glomeruli.

Classic tetrad:

1. Palpable purpura — non-blanching, palpable (not flat), concentrated on the buttocks and lower extremities. The distribution is gravitational — the most dependent areas are most affected. This is the hallmark finding and is present in virtually all cases.
2. Arthritis or arthralgia — typically affecting the knees and ankles; non-migratory; transient and self-limiting.
3. Abdominal pain — colicky, from IgA deposition in bowel vasculature. Can cause GI bleeding (hematochezia), intussusception, or bowel obstruction.
4. Renal involvement (IgA nephropathy) — hematuria and proteinuria from IgA glomerulonephritis. Most children have only mild, transient renal involvement, but approximately 1–5% of children and a higher proportion of adults develop progressive CKD.

Management. IgA vasculitis in children is typically managed with supportive care — hydration, analgesia (NSAIDs for arthralgia — used cautiously given renal involvement risk), and monitoring of renal function and blood pressure. Corticosteroids are reserved for severe abdominal pain, significant GI bleeding, or nephritis with nephrotic-range proteinuria. Spontaneous resolution occurs in most children within 4–6 weeks. Adults have a higher rate of renal progression and warrant closer nephrology follow-up. See CKD and ESRD nursing for renal monitoring guidance.

Nursing priorities:

• Monitor urine for hematuria and proteinuria at every encounter during the acute phase.
• Monitor blood pressure — hypertension signals significant renal involvement.
• Assess abdominal pain carefully — intussusception is a surgical emergency in the IgA vasculitis context.
• The purpura is non-blanching; confirm this with glass/diascopy — blanching purpura has a different differential.

ANCA testing: c-ANCA vs p-ANCA

When to test. ANCA testing is indicated when the clinical presentation suggests small-vessel vasculitis — combinations of glomerulonephritis, pulmonary infiltrates or hemoptysis, upper airway destruction, or multiple organ dysfunction in the absence of another explanation. ANCA should not be used as a screening test in non-specific presentations; false-positive p-ANCA patterns occur in IBD, drug reactions, and other inflammatory conditions.

Nursing assessment priorities

Vasculitis assessment is multisystem by necessity — the inflammatory process can damage any vascular bed. Nurses must assess across six domains simultaneously.

Vascular compromise

• Peripheral pulses: document presence, character, and symmetry in all four extremities at baseline and at each assessment.
• Blood pressure in both arms: a differential >10 mmHg suggests subclavian or aortic arch involvement (Takayasu, GCA).
• Skin color, temperature, and capillary refill: pallor, cyanosis, or mottling of extremities signals ischemia.
• Digital ischemia: fingertip or toe ulcers, gangrene — assess carefully in Takayasu and medium-vessel disease.
• Livedo reticularis: mottled, net-like skin pattern indicating dermal vessel inflammation — a sign of medium-vessel vasculitis, APS, or cryoglobulinemia.

Renal function

Renal involvement is the leading driver of long-term morbidity in AAV. Monitor at every encounter:

• BUN and serum creatinine — rising creatinine in a vasculitis patient is an emergency, not a trend to watch over weeks.
• Urinalysis: hematuria and RBC casts (dysmorphic red cells in urine sediment = glomerulonephritis until proven otherwise), proteinuria.
• Urine protein-to-creatinine ratio: more reliable than spot urine dipstick for quantifying proteinuria.
• Blood pressure: hypertension from glomerulonephritis or renal artery involvement.

Anemia is common in vasculitis — both anemia of chronic inflammation and iron-deficiency from GI or pulmonary blood loss. See anemia nursing reference for assessment and monitoring framework.

Respiratory

Pulmonary involvement ranges from asymptomatic nodules to life-threatening alveolar hemorrhage:

• Hemoptysis: any blood-tinged sputum in a vasculitis patient requires urgent evaluation — diffuse alveolar hemorrhage (DAH) is a medical emergency.
• Dyspnea, tachypnea, decreasing SpO₂: monitor closely in GPA, MPA, and EGPA.
• Eosinophil count: monitor in EGPA — eosinophilia above 1,500/µL during active disease; may normalize with corticosteroids (complicating the diagnosis if treatment precedes testing).
• Chest radiograph and CT findings: cavitating nodules in GPA, bilateral infiltrates in DAH.

ENT assessment

Upper airway involvement is characteristic of GPA and is often the presenting complaint:

• Sinusitis that does not respond to antibiotics, or chronic mucopurulent nasal discharge
• Recurrent epistaxis
• Oral and nasal ulcers
• Subglottic tenderness or stridor (subglottic stenosis is a GPA complication requiring ENT referral)
• Nasal bridge deformity: ask about progressive collapse of the nasal bridge — saddle-nose deformity is a late structural consequence of GPA

Skin

Skin findings provide clues to both the type and activity of vasculitis:

• Palpable purpura: raised, non-blanching lesions on the lower extremities — small-vessel vasculitis (AAV, IgA vasculitis, cryoglobulinemic vasculitis). Unlike flat petechiae, these are raised to the fingertip.
• Livedo reticularis: net-like mottling of the skin from dermal arteriole involvement.
• Skin ulcers: painful ulcers over pressure points or lateral malleoli — medium-vessel disease.
• Digital ischemia: Raynaud’s phenomenon, digital tip ulcers, or frank gangrene in large or medium vessel disease.

Constitutional and neurologic

• Fever, fatigue, weight loss, and night sweats accompany active vasculitis of any type — these are non-specific but important markers of systemic inflammation.
• Headache: in the appropriate age and demographic, new-onset temporal headache is GCA until proven otherwise.
• Jaw claudication: specific for GCA — jaw pain or fatigue while chewing.
• Mononeuritis multiplex: new-onset foot drop, wrist drop, or sensory loss in an asymmetric distribution — hallmark of medium-vessel vasculitis involving the vasa nervorum (PAN, EGPA).
• Visual symptoms: any visual change in a patient over age 50 with headache requires same-day evaluation for GCA.

Patients on immunosuppressive therapy are at elevated risk for opportunistic infections, including sepsis from bacterial, fungal, and viral pathogens. Review sepsis nursing for early recognition criteria. Patients receiving cyclophosphamide or rituximab are also at risk for complications similar to organ transplant recipients — see organ transplant nursing for immunosuppression monitoring principles.

Pharmacology: vasculitis treatment regimens

Vasculitis vs other conditions: NCLEX differentiation

For detailed coverage of comparison conditions, see lupus nursing, rheumatoid arthritis nursing, and scleroderma nursing.

12 NCLEX tips for vasculitis

These are the highest-yield testing points on vasculitis for NCLEX-RN and NCLEX-PN:

1. GCA + vision change = same-day emergency. Any patient over 50 with suspected giant cell arteritis who develops blurred vision, diplopia, or sudden vision loss must be started on high-dose corticosteroids immediately. Anterior ischemic optic neuropathy from GCA causes permanent vision loss if treatment is delayed — do not wait for biopsy results.

2. c-ANCA = GPA (Wegener’s). The cytoplasmic ANCA pattern, confirmed by anti-PR3 ELISA, is the serologic signature of granulomatosis with polyangiitis. NCLEX pairs c-ANCA with the ENT–lung–kidney triad. p-ANCA/MPO identifies MPA and EGPA.

3. Saddle-nose deformity = GPA. Progressive collapse of the nasal bridge from cartilage destruction by granulomatous inflammation is essentially diagnostic of GPA in the right clinical context. It distinguishes GPA from other vasculitides that do not affect the nasal cartilage.

4. Kawasaki + aspirin = the pediatric exception. Aspirin is normally avoided in children with viral illness due to Reye’s syndrome risk. Kawasaki disease is the one NCLEX-tested exception — aspirin is indicated and correct in this diagnosis. IVIG within the first 10 days dramatically reduces coronary artery aneurysm risk.

5. PAN + HBV, ANCA-negative, no GN. Polyarteritis nodosa is associated with hepatitis B virus, is ANCA-negative, and — critically — does not cause glomerulonephritis. If NCLEX describes a medium-vessel vasculitis with renal aneurysms but no GN, ANCA-negative = PAN. If there is glomerulonephritis, consider MPA.

6. Blood pressure in both arms. Takayasu arteritis involves the aortic arch branches — a blood pressure differential greater than 10 mmHg between arms is a key diagnostic finding and nursing assessment priority. Always document BP bilaterally in the vasculitis context.

7. Palpable purpura is raised, not flat. Palpable purpura (small-vessel vasculitis) can be felt with the fingertip — unlike flat petechiae or macular purpura. The gravitational distribution (buttocks and lower extremities) and palpability are distinguishing features on NCLEX clinical vignettes.

8. EGPA = asthma + eosinophilia + vasculitis. The three-phase progression (prodromal asthma → eosinophilic phase → vasculitic phase) and the combination of adult-onset asthma with eosinophilia above 1,500/µL and multi-organ vasculitis distinguish EGPA from the other ANCA-associated vasculitides. Cardiac disease is the leading cause of death in EGPA.

9. Hemoptysis + hematuria + RBC casts = pulmonary-renal syndrome. Simultaneous alveolar hemorrhage and rapidly progressive glomerulonephritis define pulmonary-renal syndrome — a life-threatening emergency seen in GPA and MPA. RBC casts in urine sediment confirm glomerular origin. This combination requires ICU-level care and urgent immunosuppression.

10. Cyclophosphamide + MESNA + hydration. When cyclophosphamide is given intravenously, MESNA (sodium 2-mercaptoethanesulfonate) is co-administered to prevent hemorrhagic cystitis by binding the toxic urothelial metabolite acrolein. Adequate IV hydration before and after infusion is equally critical. NCLEX tests the MESNA indication specifically.

11. IgA vasculitis (HSP) — monitor urine. Renal involvement in IgA vasculitis determines long-term prognosis. Nursing priorities include urinalysis at every encounter, blood pressure monitoring, and assessment for worsening proteinuria. Most children resolve; adults progress to CKD at higher rates. The purpuric rash distribution (buttocks and lower extremities, dependent areas) is a classic NCLEX vignette clue.

12. Jaw claudication is specific for GCA, not just a vague pain complaint. Pain or fatigue in the jaw specifically during chewing — distinct from TMJ or dental pain — is the single most specific symptom for giant cell arteritis. When a patient over 50 presents with new headache, scalp tenderness, and jaw pain while eating, the diagnosis to rule out first is GCA. No other common condition produces jaw claudication.

Key takeaways

Vasculitis is a family of conditions unified by vessel wall inflammation but separated by the size of vessel targeted, the presence or absence of ANCA, granuloma formation, and the organ systems at risk. The highest clinical stakes are in ANCA-associated vasculitis — GPA, MPA, and EGPA — where simultaneous pulmonary and renal involvement can produce life-threatening organ failure within days. For nurses, the core competencies are: recognizing the organ-specific constellations that point to a vasculitis diagnosis (saddle-nose + hematuria, temporal headache + jaw claudication, purpura + rising creatinine), understanding when findings represent an emergency requiring same-day escalation (GCA + visual symptoms, DAH + GN), and safely monitoring the heavy immunosuppression regimens that these conditions require. The sepsis nursing skill set and immunosuppression monitoring principles drawn from organ transplant nursing are directly applicable to vasculitis patients on cyclophosphamide or rituximab. Renal monitoring guidance from CKD and ESRD nursing and anemia assessment from the anemia nursing reference round out the multisystem surveillance these patients need.